Previous close | 1.4700 |
Open | 1.4300 |
Bid | 0.0000 x 1200 |
Ask | 0.0000 x 3100 |
Day's range | 1.3400 - 1.4700 |
52-week range | 1.0000 - 28.4900 |
Volume | |
Avg. volume | 198,503 |
Market cap | 5.971M |
Beta (5Y monthly) | 1.47 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.7200 |
Earnings date | 13 Nov 2020 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.00 |
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
RICHMOND, Va., January 03, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request a
Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.